Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Medindia

Study Using PARI Nebulizer Finds COPD Therapy of Nebulizer and Inhaler Combo More Effective than Inhaler Alone

MIDLOTHIAN, Va., Oct. 22 In the October supplement of USRespiratory Report, Dr. Donald Tashkin will follow-up his significant studycomparing the effectiveness of nebulizers and metered dose inhalers ...
Business Insider

Pulmotect's Positive Topline Results for Inhaled PUL-042 against COVID-19 Delivered by PARI Nebulizer

MIDLOTHIAN, Va., Sept. 29, 2021 /PRNewswire/ -- Pulmotect reported positive topline results from their randomized, placebo-controlled Phase-2 trial of PUL-042 against COVID-19. Patients treated with ...
TipRanks on MSN

Savara issues patent for Molbreevi from European Patent Office

Savara (SVRA) announced the European Patent Office has issued patent No. 4 496 611 titled, “Drug-Device Combination Comprising a Liquid Solution ...
Business Insider

PARI Nebulizer Used in New Study with Pulmotect's Inhaled PUL-042 for COVID-19

MIDLOTHIAN, Va., May 7, 2020 /PRNewswire/ -- This week, the first patients are enrolling in two phase 2 clinical trials for COVID-19 using Pulmotect's PUL-042, an inhaled immunomodulatory agent to ...
Medindia

PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial

MIDLOTHIAN, Va., March 10 PARI's LC STAR nebulizer andPRONEB Ultra II compressor are the exclusive delivery devices for InspirePharmaceuticals' (Nasdaq: ISPH) second Phase 3 clinical trial for a ...
FiercePharma

PARI snags FDA approval for cystic fibrosis nebulizer platform

Respiratory devicemaker PARI picked up an approval from the FDA for its eRapid nebulizer system, which is the first electronic one to deliver Genentech's cystic fibrosis treatment Pulmozyme. A ...